文献速递脑血管病

抗血小板治疗、脑微出血与脑出血:一项Meta分析

Antiplatelet Therapy, Cerebral Microbleeds, and Intracerebral Hemorrhage: A Meta-Analysis.
PubMed 文献 · Stroke · 2018-05-24

该Meta分析检索PubMed和EMBASE从1997年1月1日至2017年12月1日的相关研究,纳入37项研究共20988名参与者,发现抗血小板治疗使用者脑微出血更常见(合并OR 1.21,95%CI 1.07-1.36,P=0.002),且与严格脑叶微出血相关(OR 1.45,95%CI 1.15-1.84,P=0.002),在抗血小板使用者中,有脑微出血者脑出血发生率高于无脑微出血者(OR 3.40,95%CI 2.00-5.78,P=0.000)。

要点

  • 抗血小板治疗使用者脑微出血更常见,合并OR 1.21(95%CI 1.07-1.36,P=0.002)。
  • 抗血小板治疗与严格脑叶微出血相关(OR 1.45,95%CI 1.15-1.84,P=0.002)。
  • 抗血小板使用者中,有脑微出血者脑出血发生率高于无脑微出血者(OR 3.40,95%CI 2.00-5.78,P=0.000)。

核心结论

  • 抗血小板药物使用与严格脑叶微出血风险增加相关,并增加有脑微出血参与者的脑出血发生率。

研究设计与样本

  • Meta分析,检索PubMed和EMBASE从1997年1月1日至2017年12月1日的相关研究,纳入37项研究共20988名参与者。

主要发现

  • 抗血小板使用者脑微出血较非抗血小板使用者更常见(合并OR 1.21,95%CI 1.07-1.36,P=0.002)。
  • 抗血小板治疗与严格脑叶微出血显著相关(OR 1.45,95%CI 1.15-1.84,P=0.002),与深部/幕下微出血的关联未达统计学显著(OR 1.37,95%CI 0.98-1.90,P=0.062)。
  • 在抗血小板使用者中,有脑微出血者脑出血发生率高于无脑微出血者(OR 3.40,95%CI 2.00-5.78,P=0.000)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Antiplatelet therapy is associated with the presence of cerebral microbleeds (CMBs) with limited studies. We further investigate the topic focusing on different effects of antiplatelet therapy on strict lobar and deep/infratentorial MBs. METHODS: We searched PubMed and EMBASE from January 1, 1997 to December 1, 2017, for relevant studies, calculated the pooled odds ratios (OR) for CMB incidence and distribution (strictly lobar, deep/infratentorial) in antiplatelet users versus nonantiplatelet users and calculated the OR for the incidence of intracerebral hemorrhage in antiplatelet users with CMBs versus those without. RESULTS: We included 20 988 participants from 37 studies. CMBs were more frequent in antiplatelet users than those in nonantiplatelet users (pooled OR, 1.21; 95% confidence interval, 1.07-1.36; P=0.002). There was a significant association of antiplatelet therapy with strictly lobar MBs (OR, 1.45; 95% confidence interval, 1.15-1.84; P=0.002) rather than deep/infratentorial MBs (OR, 1.37; 95% confidence interval, 0.98-1.90; P=0.062). Intracerebral hemorrhage incidence was higher in participants with CMBs than those without CMBs (OR, 3.40; 95% confidence interval, 2.00-5.78; P=0.000) in antiplatelet users. CONCLUSIONS: Antiplatelet drug use was associated with increased risk of strictly lobar MBs and increased the intracerebral hemorrhage incidence in participants with CMBs.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Qiu J, Ye H, Wang J, et al. Antiplatelet Therapy, Cerebral Microbleeds, and Intracerebral Hemorrhage: A Meta-Analysis. Stroke. 2018. PMID: 29798835. doi:10.1161/STROKEAHA.118.021789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。